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SUMMARY 
 
Chronic obstructive pulmonary disease is a major cause of mortality and there is a 
lack of available drugs that reduce the decline in lung function seen with disease 
progression. Therefore, there is clearly an unmet need for new therapeutics. 
Previously, we have shown that calcium-sensing receptor (CaSR) activation elicits 
airways hyper-responsiveness and inflammation in pre-clinical in vivo murine models 
of asthma. However, the role of CaSR in the progression of COPD is currently 
unknown. In this presentation, a role for CaSR and topical calcilytic therapies will be 
proposed and discussed to reduce COPD pathogenesis and disease progression. 
The proposal is supported by new data on the anti-inflammatory effects of the 
inhaled negative allosteric CaSR modulator or calcilytic, NPS89636. The effects of 
NPS89636 were studied in an in vivo model of COPD induced in guinea pigs by 
inhalation of lipopolysaccharide (LPS); as in human subjects with COPD, pulmonary 
inflammation, airways obstruction and remodeling in the guinea pig lungs were 
previously shown to be insensitive to inhaled corticosteroids. Here, we show that 
treatment with NPS89636 reduced inflammation, specifically leukocyte and 
neutrophil infiltration, in the airways of LPS-treated animals. In addition, calcilytic 
treatment reduced lung interstitial wall thickening. These effects were unlikely 
attributable to off-target calcilytic actions on the parathyroid glands, as free ionised 
blood calcium levels were not altered for up to 24 hours after calcilytic inhalation. 
Together, these observations suggested that topically delivered calcilytics may 
represent a novel treatment strategy for COPD. 
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INTRODUCTION 
 
The World Health Organization reports that chronic obstructive pulmonary disease 
(COPD) is currently the 5th leading cause of death worldwide. The disease is 
characterised by progressive and irreversible decline in lung function caused by 
airway remodeling associated with chronic inflammation of the small airways and 
lung parenchyma [1]. The disease is triggered by an abnormal response to inhaled 
particles and gases, most commonly cigarette smoke [1]. Unlike asthma, the airways 
inflammation in COPD appears to be driven by neutrophils, which are not susceptible 
to inhibition by high doses of corticosteroids [1, 2], so that current therapeutic 
strategies are largely palliative. Clearly, there is an unmet clinical need to identify 
novel therapeutic agents that may alter the natural history of the disease [1].  
 
New therapeutic strategies for COPD targeting airways hyper-responsiveness, 
remodeling or inflammation, are under investigation. These include anticholinergic 
bronchodilators, drugs suppressing mitogen activated protein kinase (MAPK), 
phosphoinositide-3 kinase (PI-3K), Rho kinase (RhoK) and phosphodiesterase-4, 
leukotriene and chemokine receptor blockers, neutrophil elastase inhibitors and 
antibodies against TNF-α [1, 3]. In addition, there is evidence that activation of 
arginase participates in the airways remodeling and inflammatory response in 
patients with COPD and animal surrogates [4, 5], suggesting that arginase could be 
targeted for COPD treatment.  
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Recently, we have identified a possible link between the activation of arginase and 
the development of airways inflammation and hyperresponsiveness via L-arginine-
derived polyamines and activation of the airways calcium-sensing receptor (CaSR) 
[6]. CaSR is a G protein-coupled receptor that signals by augmenting intracellular 
calcium [6-8], activating RhoK [8, 9], phosphorylating MAPK/ERK, activating PI-
3K/Akt [6-8] and reducing intracellular cAMP concentrations [6-8]. While Ca2+ is the 
physiological ligand of the CaSR, many other polyvalent cations and polycations can 
activate it, including divalent cations (Cd2+ and Ni2+), trivalent cations (Gd3+ and La3+) 
and arginase-derived polyamines (spermine, spermidine, putrescine) [6, 7]. Other 
polycationic compounds implicated in the pathogenesis of obstructive airways 
disease, including eosinophil-derived major basic protein [10] and other cationic 
proteins [11, 12], are also agonists of the CaSR [6]. The CaSR is pivotal in 
extracellular Ca2+ homeostasis and its expression is highest in the tissues involved in 
the control of mineral ion metabolism, namely the parathyroid glands, kidneys and 
bone [7, 13]. Indeed, pharmacological CaSR activators have been developed for the 
treatment of genetic and acquired disorders of mineral ion metabolism caused by 
defective CaSR expression or function [13]. For example, calcimimetics such as 
cinacalcet (Sensipar, Mimpara) have been on the market since 2004 for the 
treatment of tertiary hyperparathyroidism. Conversely, calcilytics were developed by 
NPS Pharmaceuticals (now Shire), GSK, Novartis and Japan Tobacco initially as 
possible novel therapeutic agents for the prophylaxis of osteoporosis, but their 
development has since been discontinued owing to lack of efficacy [14, 15]. 
NPS/Shire is currently repurposing its calcilytics for a rare disease (autosomal 
dominant hypocalcaemia with hypercalciuria) caused by activating CaSR mutations 
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[16].  With our recent report of the efficacy of calcilytics in the airway [6], there is now 
increasing interest in the repurposing of CaSR modulators for lung disease. 
In addition to its prominent role in the regulation of free ionized Ca2+, the CaSR is 
expressed in tissues not known to be involved in divalent cation homeostasis such 
as airways epithelial and smooth muscle cells, as well as in monocytes and 
eosinophils [6, 17, 18].  Based on these findings, we have demonstrated that 
calcilytics delivered directly to the airways exhibit the potential to abrogate 
hyperresponsiveness and inflammation in allergic asthma [6]. Furthermore, the 
CaSR has been implicated in regulating epithelial cell adhesion [9], particularly in 
human oesophageal epithelial cells where CaSR stimulation decreases the 
expression of intercellular adhesion molecules [19]. Polycations can also enhance 
epithelial permeability in guinea pig trachea [20], indicating a possible role for the 
CaSR signalling in mediating the loss of epithelial cell integrity, as observed in 
obstructive airways diseases including COPD. Finally, mucus overproduction is one 
of the cardinal clinical features of obstructive airways diseases, particularly COPD. It 
was demonstrated recently that CaSR activation underlies hypoxia-induced mucus 
hypersecretion in cultured human epithelial cells [21], providing yet another 
precedent for therapeutic benefit calcilytics in COPD.  
Despite these accumulating data there is presently no direct evidence that the CaSR 
is involved in the pathogenesis of COPD and that CaSR inhibition can abrogate 
COPD-associated airways inflammation and remodeling. Consequently, we set out 
in this study to establish such evidence in a pre-clinical surrogate of COPD in vivo, 
incorporating delivery of the CaSR inhibitor by inhalation, which is putatively most 
appropriate to the management of airways disease and is likely to minimise systemic 
unwanted effects. 
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METHODS 
Animal experiments 
All animal procedures were approved by local ethical review and conformed to the 
regulations of the UK Home Office according to the Animals (Scientific Procedures) 
Act 1986 and ARRIVE guidelines [22]. Male, Dunkin-Hartley guinea pigs obtained 
from Harlan were housed in a room with a 12 hour dark/light cycle, and access to 
food and water ad libitum. Induction of COPD-like chronic neutrophilic inflammation 
was adapted from Toward et al, 2001 [23, 24]. Briefly, animals were exposed to 
nebulized lipopolysaccharide (LPS, 30 μg/ml in saline) delivered by a Pulmostar 
nebuliser (DeVilbiss, Sunrise Medical) at 0.3 mL/min driven by a constant pressure 
of 20 lb p.s.i. to a Perspex exposure chamber for one hour, on alternate days over 
eighteen days. Animals received drugs/vehicles for nine days commencing after the 
fifth LPS exposure using the same aerosol delivery technique: NPS89636 3 µM 
(vehicle: 0.03% DMSO in saline) or budesonide 0.61.2 mg/ml (vehicle: 30% DMSO, 
30% ethanol in saline), 30 min before LPS exposure (Figure 1 A).  
 
BALF analysis 
Animals were euthanized 24 hrs after the ninth exposure with intraperitoneal sodium 
pentobarbital (Euthatal, 400 mg/kg). Bronchoalveolar lavage was performed to 
determine total and differential cell counts in the bronchoalveolar lavage fluid (BALF)  
as described previously [25]. Briefly, phosphate buffered saline (PBS) (1 mL per 
100g weight of animal) was instilled into the airways through a polypropylene 
cannula inserted into trachea, and then gently aspirated, and the procedure was 
repeated twice. Total BALF cells were counted immediately using a Neubauer 
haemocytometer. For differential cell counts, cells in the BALF were immobilised on 
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slides using the Shandon Cytospin 3 and then submerged in 1.5% Leishman’s stain 
in methanol, and cells were counted using microscope with a 100x oil immersion 
objective. For immunofluorescence, the BALF cells were allowed to adhere to a 
glass slide for 1 hour at room temperature, and then fixed with 2% formalin for 15 
mins. Cells were blocked and permeabilized with 0.1% Tween-20 and 1 mg/ml 
bovine serum albumin in PBS for 2 hours, and samples incubated with rabbit anti-
CaSR antibody (1:100, Abcam) for 2 hours. After washing, the secondary antibody 
(goat anti-rabbit Alexa 594, 1:200 Invitrogen, Thermo Fisher Scientific, Waltham, MA 
USA) was applied for 1 hour and nuclei were counterstained with Hoechst (1:10000) 
for 20 minutes. Negative control staining was performed by omitting the primary 
antibody. Images were acquired using an Olympus BX61 upright epifluorescence 
microscope and a 100x oil objective. 
 
Blood calcium analysis 
Whole blood was collected from the carotid artery, allowed to clot overnight at 4 °C 
and then centrifuged (3,000g for 10 min at 4 °C). Free Ca2+ determinations were 
performed on supernatant serum by the Clinical Biochemistry service (Heath 
hospital, Cardiff, UK) using a calcium electrode (Radiometer ABL800 Flex). 
 
Histology  
Half of the lung was clamped and infused with neutral buffered formalin solution, 
then placed in a tube containing the solution for a further 24 hours. Fixed lungs were 
then embedded in paraffin wax. Five μm sections were cut and stained with 
haematoxylin and eosin (H&E) using a Leica Autostainer XL (Leica Microsystems, 
Milton Keynes, United Kingdom) according to the manufacturer’s protocol, and 
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histopathology scoring was performed by a pathologist who was ignorant of the 
treatments. Grades of 4 to 5 were given for samples that had increased fibrosis with 
definite damage to lung architecture with formation of fibrous bands or small fibrous 
mass.  
 
Drugs and materials 
NPS89636 was a gift from NPS Pharmaceuticals, Inc. All other chemicals purchased 
from Sigma-Aldrich (Dorset, UK) unless otherwise stated.  
 
Data analysis 
Data were analysed using Microsoft Office Excel (Microsoft Corporation) and Prism 6 
(Graph Pad Inc.). Student’s two-sided, unpaired t-test was used to compare groups 
of two data sets, and one-way ANOVA with the Bonferroni post hoc test used to 
compare three or more data sets. All results are shown as mean ± standard error of 
the mean (SEM), with n being the number of animals. 
 
RESULTS AND DISCUSSION  
It is well established that corticosteroids have little effect on COPD progression. 
Specifically, inhaled corticosteroids do not reduce neutrophilic inflammation in 
patients with COPD [1]. Neutrophil infiltration into the airways of guinea pigs 
following acute exposure to LPS, an agent present in tobacco smoke, was shown to 
be insensitive to treatment with inhaled budesonide [26], and was only partially 
sensitive to systemic dexamethasone [23]. Here we show that inhaled budesonide 
does not significantly alter total, macrophage, neutrophil, eosinophil and lymphocyte 
infiltration into the BALF of guinea pigs chronically treated with LPS (Figure 1), 
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echoing observations in patients with COPD [1]. In contrast, inhalation of the 
calcilytic, NPS98636 (3 µM) prior to LPS exposure significantly reduced total 
leukocyte counts, as well as neutrophil, eosinophil and lymphocyte infiltration into 
airways of LPS-treated animals (Figure 2 A, C ,D ,E). Moreover, calcilytic inhalation 
significantly reduced LPS-induced interstitial wall thickening (Figure 3).  
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Figure 1. The inhaled corticosteroid, budesonide, did not affect leukocyte infiltration 
into the BALF of LPS-treated guinea pigs sampled at Day 18. LPS and budesonide 
or calcilytic treatment protocol used in the present study (A). Effect of vehicle, 0.6 
mg/ml, or 1.2 mg/ml budesonide inhalation on total (B) and differential (macrophages 
(C), neutrophils (D), eosinophils (E), and lymphocytes (F)) cell counts in BALF from 
chronically LPS-treated guinea pigs. Each data point represents mean ± SEM, 
n=410. Performed using a one-way ANOVA with Bonferroni post hoc test; ns = not 
significant (p > 0.3). 
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Figure 2. An inhaled calcilytic, NPS89636, suppressed leukocyte infiltration into the 
BALF of LPS-treated guinea pigs on Day 18 of the protocol shown in Fig 1. Effect of 
NPS89636 (NPS89, 3 µM) on total (A), and differential macrophage (B), neutrophil 
(C), eosinophil (D) and lymphocyte (E) cell counts in the BALF, and free ionised 
calcium concentration in blood (F) in chronic LPS-treated and untreated (naïve) 
guinea pigs. Each data point represents the mean ± SEM, n=512. Statistical 
comparison done by one-way ANOVA with Bonferroni post hoc test; *p < 0.05, **p < 
0.01, ***p < 0.001. 
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Figure 3. Histology of lungs from LPS-treated guinea pigs from Figure 2.  
Interstitial wall thickening (A), thickening of the tunica media (B), and % area of 
grade 4 or 5 (fibrotic histology) (C) in absorbance units (AU) were increased in the 
LPS-treated Guinea pigs (vehicle) compared with naïve animals. These effects were 
significantly reduced by the calcilytic NPS89636 (NPS89, 3 µM). Each data point 
represents mean ± SEM, n=2 (naïve) and n=12 (vehicle and NPS98). 
Representative images of the sections from naïve (D), vechicle (E) or calcilytic (F) 
pre-treated airways stained with H&E. Unpaired t-test, **p < 0.01. 
 
Systemic calcilytics were initially developed to target the parathyroid gland CaSR to 
evoke oscillating plasma parathyroid hormone (PTH) levels, a known anabolic 
stimulus [13]. To test whether the beneficial effects of inhaled calcilytics could be 
ascribed to their systemic actions via the parathyroid CaSR, we measured ionised 
calcium concentrations in the blood of challenged animals, and found that the mean 
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concentration was not significantly altered following calcilytic inhalation, indicating 
that changes in PTH are unlikely to be responsible for the reduction in inflammation 
produced by inhaled calcilytics (Figure 2F).  
Finally, a role for the CaSR receptor signalling in inflammatory responses is 
becoming more apparent. Being an integrating component of the inflammasome, the 
CaSR appears to be the key to monocyte and macrophage activation [17, 27, 28] 
and migration to sites of inflammation [29]. It is also known that CaSR expression 
itself is upregulated by pro-inflammatory cytokines [6, 30, 31], creating grounds for a 
vicious cycle that further amplifies the immune response. Here we show that the 
CaSR is expressed in BALF cells from naïve guinea pigs (Figure 4 A), confirming 
that it has the propensity to participate in pathological processes in the airways 
including COPD (Figure 5). Identification of the precise mechanisms whereby 
calcilytics inhibit these processes in COPD requires further investigation. 
 
 
Figure 4. Immunocytochemistry of BALF leucocytes from naïve guinea pigs.  
A) BALF cells stained with CaSR antibody (red) and nuclear stain (Hoechst, blue) 
show immunoreactivity for CaSR. B) Negative control. 
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Figure 5. Proposed CaSR signalling mechanisms contributing to COPD.  
Irritants present in tobacco smoke or pollutants (such as Cd2+, Ni2+, Gd3+ and La3+) 
may stimulate CaSR expressed in macrophages and epithelial cells, activating them 
and promoting inflammatory mediator secretion. Attracted inflammatory cells release 
proteases, growth factors and cytokines that can lead to fibrosis, goblet cell 
hyperplasia, mucus overproduction and smooth muscle cellular proliferation. 
Polycations released by inflammation, attract monocytes and neutrophils, and further 
activate smooth muscle and epithelial cells setting the scene for a positive feedback 
loop sustaining the inflammatory process.  
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CONCLUSIONS 
Our data are consistent with the hypothesis that calcilytics targeting the CaSR 
represent a novel therapeutic approach in the management of COPD. We 
demonstrate here that pre-treatment with an inhaled calcilytic can decrease steroid-
resistant neutrophilic inflammation and attenuate airways remodeling in an animal 
COPD surrogate even when administered late in the course of LPS challenge. 
Calcilytic drugs were demonstrated to have an acceptable safety profile in clinical 
trials in humans, albeit lacking efficacy for the prophylaxis and treatment of 
osteoporosis. The re-purposing of calcilytics as topically deliverable drugs targeting 
chronic obstructive pro-inflammatory airway disorders offers a tantalising alternative 
to current methods of disease management. 
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